Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2014

Filed with the SEC on May 9, 2014 and accepted by EDGAR at May 9, 2014, 12:46 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2014-01-01 to 2014-03-31$96.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2014-01-01 to 2014-03-31−$405.9kus-gaap:OperatingIncomeLoss
Interest expense3 months2014-01-01 to 2014-03-31$95.4kus-gaap:InterestExpense
Net income3 months2014-01-01 to 2014-03-31−$501.3kus-gaap:NetIncomeLoss
Basic EPS3 months2014-01-01 to 2014-03-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow3 months2014-01-01 to 2014-03-31−$90.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2014-03-31$70.5kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-03-31$71.8kus-gaap:AssetsCurrent
Total assetsAt period end2014-03-31$71.8kus-gaap:Assets
Total liabilitiesAt period end2014-03-31$185.0kus-gaap:Liabilities
Shareholders' equityAt period end2014-03-31−$113.2kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-14-002379. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.